MRA Group’s Post

📊 In the age of huge data sets, AI and innovative chemistry, how do you decide which molecules from your vast libraries have potential early on? 🔬When cell culture doesn’t provide the context of a complex biological system and organoids aren’t scalable enough, how do you bridge the gap between in vitro and mammals? 💡What if you could screen hundreds of thousands of compounds in vivo within weeks for a few £s per compound? 📍Come and visit our booth in the breakthrough zone - BZ10 - to find out more #elrig #elrigdd24 #drugdiscovery #HTS

Join Blake Mandell from Transcend Therapeutics at the upcoming Fierce Biotech Summit on Sept 30 - Oct 1 in Boston as he shares his expertise in groundbreaking biotech innovations and advancements. Register now and save up to $500 with the Early Bird Rate: https://ow.ly/uTAE50SyYgy Learn, Network and Connect over two jam-packed days with 500+ industry leaders and gain valuable insights into the future landscape of biotech. Stay Updated on all our events by following Fierce Life Sciences Events #FierceBiotechSummit #WeAreFierce #FierceBiotech #FierceBiotechSummit #BiotechInnovation #LifeSciences #PharmaIndustry #BiotechLeaders #Biotech2024 #BiotechTrends

Discovery chemists, ever dream of traveling from “data in” to “data out” along a path that includes entity registration? A DMTA workflow that saves you time and protects your investment? We've built the road. Meet some of its trailblazers on our July 31st webinar, including Steve Unger, Department Head and Director of Informatics at Pliant Therapeutics. Register for *Catalyzing DMTA Information into Insights* at https://lnkd.in/eBwDuFSw #medicinalchemistry #dmta #cheminformatics #drugdiscovery

A big day at Juvena Therapeutics, as their lead candidate, JUV-161, has received positive FDA feedback and Orphan Disease Designation (ODD) for the treatment of Myotonic Dystrophy Type 1 (DM1). This is a major win for the broader ecosystem as an example of how founder-led biotech can truly change how we think of addressing unmet medical needs. As an early investor, I take immense pride in the team's dedicated efforts over the course of five and a half years, involving hard work and determination, to establish a world-class, fully integrated platform for the discovery and development of biologics. Their unique approach to repairing and restoring muscle health with a biologic that enhances muscle regeneration, metabolism, and function, countering the effects of aging and degenerative disease. Congrats Hanadie Yousef, Jeremy O'Connell, Neil Berkley, Mo Tabrizi, all the scientists, biologists, engineers, rest of the team, other investors, and the many partners who have believed in this group. Big things ahead!!! 🚀 Link to the announcement: https://lnkd.in/gvRTC2NS #biotech #venturecapital #founderled #healthcare #MyotonicDystrophy #RareDisease #unmetmedicalneed #healthspan #sarcopenia

Discover how leading life science companies are overcoming challenges and raising significant funds to drive innovation! This panel will feature industry leaders discussing their unique scientific pursuits, products, and the financial and regulatory hurdles in today’s competitive life sciences market. 🎤 Speakers include: Jang-Ho Cha, Latus Therapeutics Josh Muntner, CFO, Imvax, Inc. Moderated by John Pennett, EisnerAmper Advisory Services. Join us for this insightful session at the Philly Builds Bio+ Third Annual Symposium! 🔗 Register today: phillybuildsbio.org #PhillyBuildsBio #LifeSciences #InvestmentOpportunities #FinancingSuccess #BiotechInnovation

❗𝗪𝗔𝗥𝗡𝗜𝗡𝗚: 2 Discounted Passes Left for the 𝟲𝘁𝗵 𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲-𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗦𝘂𝗺𝗺𝗶𝘁!   Time is running out to be part of the 𝗺𝗼𝘀𝘁 𝗰𝗿𝘂𝗰𝗶𝗮𝗹 𝗲𝘃𝗲𝗻𝘁 𝗶𝗻 𝗺𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀. Don't risk falling behind as top experts 𝗰𝗼𝗻𝗳𝗿𝗼𝗻𝘁 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗽𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 and share their 𝘀𝗲𝗰𝗿𝗲𝘁𝘀 𝗼𝗻 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀.   𝗚𝗿𝗮𝗯 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 - https://ter.li/ntamqp   Once these 2 passes are gone, so is your chance to stay ahead in this fast-evolving field.   ⏳ 𝗦𝗮𝘃𝗲 $𝟯𝟬𝟬 𝗯𝘆 𝗺𝗶𝗱𝗻𝗶𝗴𝗵𝘁 𝘁𝗼𝗺𝗼𝗿𝗿𝗼𝘄 - https://ter.li/ook4wg   Don't let this opportunity slip away!   #MacrophageDirectedTherapiesSummit

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Allogene's $110M offering; Apellis refinances: Plus, news about FogPharma, Artbio, Enveric, MindBio and Allozymes: Allogene taps investors for $110M: The biotech priced a common stock offering that included mutual funds, institutional investors and healthcare specialists. Some board members and executives also took part in the financing. The Bay Area biotech now has rights in the EU and UK for the allogeneic cell therapy called cemacabtagene ansegedleucel. — Kyle LaHucik Apellis refinances: The commercial-stage biotech received about $375 million in a credit facility from investment firm Sixth Street. About $326 million went to buy out a development liability with SFJ Pharmaceuticals, and the net proceeds were about $32 million. — Kyle LaHucik FogPharma teams up with Artbio: The biotechs plan to co-develop 212Pb alpha radioligand therapies and will “contribute equally” across R&D and commercialization. No financials were disclosed. Both startups have raised large financing rounds in the past six months. — Kyle LaHucik Enveric, MindBio sign term sheet partnership: Enveric is out-licensing one of its “novel psilocin prodrug” programs to MindBio. If the companies opt to sign into a “definitive agreement,” MindBio could receive up to $66.5 million in upfront and milestone payments, as well as royalties ranging from 2.5% to 10% on all future sales. — Max Gelman Allozymes raises $15M Series A: The Singapore-based company plans to use the money to expand to Europe and find new partners in both the food and pharma industries. Allozymes said it has capabilities in enzyme screening, sorting and detection that use AI and machine learning algorithms. — Max Gelman #lucidquest #genetherapy #celltherapy

It's clear that the Annual Meeting is more than just a conference; it's a catalyst for sparking ideas, forming relationships, and advancing progress. As Joe Lewcock, Ph.D., Chief Scientific Officer of Denali Therapeutics, eloquently expressed, "I can see it's been incredibly impactful to be involved, not just through the consortia... but through the relationships we've built at this meeting." Together, we're driving groundbreaking advancements in ALS research. #ALSResearch #EveryoneLives #ALS #EndALS #ALSAwarenessMonth

𝐈𝐃𝐑𝐱'𝐬 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐢𝐨𝐧 𝐨𝐟 𝐚𝐧 𝐨𝐯𝐞𝐫𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞𝐝 𝐒𝐞𝐫𝐢𝐞𝐬 𝐁 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐧𝐠 IDRx has announced the successful completion of an oversubscribed $120M Series B financing, led by RA Capital Management, Commodore Capital, and Blackstone Multi-Asset Investing. The funds will support the ongoing Phase 1/1b StrateGIST 1 study of IDRx's lead candidate, IDRX-42. Key highlights: • Fast Track designation granted by the U.S. FDA for IDRX-42. • Promising preliminary Phase 1 data, showing a 43% ORR in second-line GIST patients. • Strong backing from top-tier investors, including RA Capital, Andreessen Horowitz, and Merck KGaA. This milestone brings IDRx closer to its goal of transforming GIST treatment with precision therapies designed to address treatment resistance and adverse events. The company expresses its gratitude to the dedicated team, partners, and investors who continue to support its mission to elevate the standard of care for GIST patients. #Biotech #PrecisionMedicine #Oncology #GIST #ClinicalTrials 

From a layman perspective, knowing which clinical trials are interesting or not can be difficult. I spoke to Dr Bianca Ogden from Platinum Asset Management and Hashan De Silva, CFA from KP Rx about what they are watching and which innovations they are most excited about. #biotech #investing https://lnkd.in/gd8CwYas